Benzinga · Mar 6, 2026
TV
NASDAQ · TVGNW
Tevogen Bio Holdings Inc.
Healthcare · Biotechnology
$0.06
Down-$0.00 (-0.33%)
Updated Oct 7, 2026, 6:23 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 9.25M
- P/E ratio
- -2.7
- Dividend yield
- 0.00%
- 52-week range
- $0.03 – $0.08
- Volume
- 368.4K
- Avg. volume
- 111.92K
Price performance · TVGNW
TVGNW price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
TVGNW closed at $0.06 after 20 trading sessions, up 14.77% for the selected period.
- Last close
- $0.06
- Period change
- +14.77%
- Period low
- $0.05
- Period high
- $0.07
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $0.0728 | $0.0728 | $0.0586 | $0.0606 | 368.4K |
| Oct 5, 2026 | $0.0612 | $0.068 | $0.0531 | $0.0637 | 121.86K |
| Oct 2, 2026 | $0.067 | $0.073 | $0.0603 | $0.0613 | 306.95K |
| Oct 1, 2026 | $0.0685 | $0.073 | $0.0604 | $0.0605 | 269.98K |
| Sep 30, 2026 | $0.0699 | $0.075 | $0.0601 | $0.0695 | 221.05K |
| Sep 29, 2026 | $0.0685 | $0.0698 | $0.0601 | $0.0601 | 286.57K |
| Sep 28, 2026 | $0.07 | $0.072 | $0.0586 | $0.0601 | 306.42K |
| Sep 25, 2026 | $0.0706 | $0.075 | $0.0541 | $0.065 | 470.46K |
| Sep 24, 2026 | $0.0505 | $0.075 | $0.0505 | $0.0607 | 513.98K |
| Sep 23, 2026 | $0.055 | $0.0649 | $0.0502 | $0.0607 | 505.2K |
| Sep 22, 2026 | $0.055 | $0.0649 | $0.0483 | $0.0549 | 592.07K |
| Sep 18, 2026 | $0.056 | $0.057 | $0.0545 | $0.055 | 436.09K |
| Sep 17, 2026 | $0.0547 | $0.057 | $0.048 | $0.055 | 453.67K |
| Sep 16, 2026 | $0.054 | $0.057 | $0.0472 | $0.0529 | 684.71K |
| Sep 15, 2026 | $0.0539 | $0.057 | $0.0494 | $0.0544 | 637.58K |
| Sep 14, 2026 | $0.052 | $0.056 | $0.049 | $0.0539 | 940.27K |
| Sep 11, 2026 | $0.0525 | $0.0535 | $0.0425 | $0.0518 | 622.62K |
| Sep 10, 2026 | $0.0469 | $0.0508 | $0.0451 | $0.0508 | 14.37K |
| Sep 9, 2026 | $0.0515 | $0.0523 | $0.0469 | $0.0514 | 192.52K |
| Sep 8, 2026 | $0.0521 | $0.0543 | $0.047 | $0.0528 | 215.55K |
Latest TVGNW news
The latest Smart Investors Daily articles mentioning TVGNW.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TVGNW research
Overview
Company profile and research snapshot.
Company profile
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · Dec 8, 2025
Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook
Tevogen Bio was recognized by NJBIZ for its innovative ExacTcell™ platform and AI technology, with projected near-term commercial potential of $1 billion in first-year revenue and a five-year forecast of $18-22 billion.
Yahoo · Nov 14, 2025
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
WARREN, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced the filing of its quarterly report on Form 10-Q for the quarter ended September 30, 2025, highlighting continued capital-efficient execution at a time when sustainability has become what the Company believes a defining challenge for the biotechnology industry. Tevogen reported a loss from operations calculated in accordance with U.S. GAAP of $5.7 million for the thre
GlobeNewswire Inc. · Nov 3, 2025
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
Tevogen Bio explains its accumulated deficit of $129 million, highlighting that the majority represents non-cash expenses and is offset by additional paid-in capital, with total cash loss under $42 million.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
